TNDM vs. NARI, IRTC, TMDX, BLCO, INSP, SLNO, PRCT, NVST, LIVN, and WRBY
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), PROCEPT BioRobotics (PRCT), Envista (NVST), LivaNova (LIVN), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.
Tandem Diabetes Care vs.
Tandem Diabetes Care (NASDAQ:TNDM) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
Inari Medical has lower revenue, but higher earnings than Tandem Diabetes Care. Inari Medical is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Tandem Diabetes Care presently has a consensus price target of $34.15, suggesting a potential upside of 52.20%. Inari Medical has a consensus price target of $69.22, suggesting a potential downside of 13.44%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Inari Medical.
Tandem Diabetes Care has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.
Inari Medical has a net margin of -13.68% compared to Tandem Diabetes Care's net margin of -14.84%. Inari Medical's return on equity of -10.09% beat Tandem Diabetes Care's return on equity.
91.0% of Inari Medical shares are held by institutional investors. 1.9% of Tandem Diabetes Care shares are held by insiders. Comparatively, 10.6% of Inari Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Tandem Diabetes Care had 7 more articles in the media than Inari Medical. MarketBeat recorded 8 mentions for Tandem Diabetes Care and 1 mentions for Inari Medical. Tandem Diabetes Care's average media sentiment score of 1.07 beat Inari Medical's score of 0.00 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
Tandem Diabetes Care received 524 more outperform votes than Inari Medical when rated by MarketBeat users. Likewise, 60.76% of users gave Tandem Diabetes Care an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
Summary
Tandem Diabetes Care beats Inari Medical on 10 of the 18 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
This page (NASDAQ:TNDM) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy TNDM Stock Free TNDM Stock Alerts